Pragmatic Semiconductor has appointed Mercedes Johnson as a Non-Executive Director on its Board, effective November 6, 2026. Johnson brings over 40 years of semiconductor industry finance and governance experience, having held senior roles at Broadcom, Lam Research, and Applied Materials, and serving on multiple tech company boards. Her expertise is expected to strengthen Pragmatic's strategic capabilities as the company advances its flexible semiconductor technology and scales operations globally. This move supports Pragmatic’s ambitions to accelerate customer adoption and expand its partner ecosystem in emerging markets.
Pragmatic Semiconductor's recent board appointment comes amid a Technology sector where 82 of 150 US stocks rose and 66 fell on Pluang as of Nov 10, 2026 14:11 WIB. Notable movers include VNET Group Inc, which rose 3.80% with a typical hold time of 17 days and 100% sell order activity, and Amplitude Inc, up 3.71% with 88% buy orders and a 32-day hold time. Workiva Inc declined 4.08%, holding an average of 22 days on the platform.
Trogenix, a clinical-stage precision oncology company, has appointed John Young as Chair and Josh Murray as Non-Executive Director to support its global strategy, commercial growth, and US expansion. John Young brings over 35 years of pharmaceutical ...
Wellington Management Group LLP has notified that it crossed the 5% voting rights threshold in Admiral Group PLC as of November 6, 2026. The group holds a total of 5.01% voting rights through direct shares and financial instruments. This disclosure i...
Equinor ASA has completed the fourth tranche of its 2026 share buyback program, repurchasing a total of 974,300 shares at an average price of NOK 420.35 per share between November 2 and 6, 2026. This brings Equinor's total holdings of its own shares ...
UBS upgraded Morgan Stanley Direct Lending Fund (MSDL) from Neutral to Buy following strong Q3 2026 net investment income of $40.3 million, beating earnings estimates. The fund declared a fourth-quarter dividend and plans fee cuts in 2027 to boost in...
Roche presented new data on its Alzheimer’s disease portfolio at the CTAD 2026 conference, highlighting advances in both pharmaceuticals and diagnostics. Key updates include Phase Ib/IIa data for trontinemab showing rapid amyloid clearance, the start...
